Codexis Reports Q1 Revenue of $15.25M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy CDXS?
Reports Q1 revenue $15.25M, consensus $14.53M. "Next week Codexis will present new data at the TIDES USA annual meeting demonstrating how the ECO Synthesis Manufacturing Platform enables control over phosphorothioate stereochemistry. Defined stereochemistry confers overall improved product quality and has the potential to deliver increased potency, a step beyond conventional manufacturing technologies," said Alison Moore, President and Chief Executive Officer of Codexis. "We finished the first quarter in a strong financial position with $65.1 million in cash, which we believe remains on track to fund anticipated operations through the end of 2027."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDXS
Wall Street analysts forecast CDXS stock price to rise
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 2.850
Low
2.00
Averages
6.00
High
11.00
Current: 2.850
Low
2.00
Averages
6.00
High
11.00
No data
About CDXS
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Codexis Q1 2026 Earnings Call Insights
- Revenue Growth: Codexis reported total revenues of $15.2 million for Q1 2026, primarily driven by the Merck technology transfer agreement, indicating ongoing growth potential in the biocatalysis sector.
- R&D Investment: The company spent $11.4 million on R&D, resulting in a net loss of $8.7 million, yet maintained a 71% product gross margin, reflecting a shift towards higher-margin products in its portfolio.
- Market Opportunities: Codexis has over 50 opportunities in its sales pipeline with 40 companies showing strong continued interest, indicating rising market recognition and demand for its new technologies.
- Future Outlook: The company reiterated its revenue guidance for 2026 in the range of $72 million to $76 million, with expectations for revenue to be more heavily weighted towards the second half, emphasizing the commercialization potential of its ECO Synthesis technology and upcoming important data releases.
See More
U.S. Stocks Decline, Dow Jones Falls Over 400 Points
- Dow Jones Decline: The Dow Jones Industrial Average fell over 400 points on Thursday, down 1.01% to 46,936.20, indicating growing concerns about the economic outlook that may dampen investor confidence.
- NASDAQ and S&P 500 Drop: The NASDAQ decreased by 1.28% to 22,425.83, while the S&P 500 also fell 1.01% to 6,707.25, reflecting widespread weakness in both tech and large-cap stocks.
- Dollar General Earnings Beat: Dollar General reported Q4 earnings of $1.93 per share, exceeding analyst expectations of $1.65, yet its stock fell approximately 7%, indicating market caution regarding future prospects.
- Commodity Market Fluctuations: Oil prices surged 8.5% to $94.64, while gold dipped 0.3% to $5,164.30, reflecting investors' search for safe-haven assets amid an uncertain market environment.
See More
U.S. Stocks Drop Over 500 Points in Morning Trading
- Market Performance: U.S. stocks opened lower on Thursday, with the Dow Jones dropping over 500 points, a decline of 1.18% to 46,860.18, indicating a weak market sentiment.
- Sector Dynamics: Financial stocks fell by 1.4% during trading, while energy shares rose by 0.4%, reflecting mixed reactions across sectors that could influence investors' asset allocation strategies.
- Jobless Claims: Initial jobless claims in the U.S. decreased by 1,000 to 213,000, below market expectations of 215,000, indicating resilience in the labor market that may positively impact economic outlook.
- International Market Reaction: Asian markets closed lower, with Japan's Nikkei 225 down 1.04% and Hong Kong's Hang Seng index down 0.70%, suggesting that global market uncertainties may affect investor confidence.
See More
CODEXIS STOCK JUMPS 65% FOLLOWING INCREASED Q4 REVENUE
- Company Performance: Codexis shares soared by 65% following a strong revenue report for the fourth quarter.
- Revenue Growth: The increase in share value is attributed to higher-than-expected revenue figures released by the company.
See More
Codexis Reports Strong Q4 2025 Results, Shares Rise
- Earnings Beat: Codexis (CDXS) reported Q4 2025 revenue of $38.9 million, reflecting approximately 81% year-over-year growth and exceeding Street forecasts by $3.1 million, primarily driven by a technology transfer agreement with Merck (MRK), indicating robust growth in the enzyme engineering sector.
- Net Income Improvement: The company achieved a net income of $9.6 million in Q4, compared to a net loss of $10.4 million in the prior year, beating consensus estimates by $0.14 per share, which signifies a substantial improvement in profitability and boosts investor confidence.
- Annual Performance Gains: Codexis reduced its net loss by approximately 33% year-over-year to $44 million, with total revenue increasing about 19% to $70.4 million, while product gross margin improved from 56% in 2024 to 64%, reflecting effective cost control and sales strategies.
- Positive Outlook: The company projects total revenue for 2026 to be between $72 million and $76 million, surpassing the consensus of $67.3 million, and indicates a cash runway extending through the end of 2027, showcasing strong financial health and future growth potential.
See More
Codexis Reports Strong Q4 and 2025 Results, Shares Surge 25%
- Significant Financial Improvement: Codexis reported a net profit of $9.6 million in Q4 2025, translating to earnings of $0.11 per share, a stark reversal from a net loss of $10.37 million in the prior year, indicating a substantial enhancement in the company's profitability.
- Revenue Surge: The company experienced an 81% year-over-year increase in total revenue for Q4 2025, reaching $38.92 million, primarily driven by the Merck Technology Transfer Agreement, showcasing its competitive edge and business expansion capabilities.
- Optimistic Future Outlook: Codexis anticipates total revenue for 2026 to range between $72 million and $76 million, reflecting a projected growth of approximately 2% to 8% from 2025, which underscores the company's confidence in future growth and sustained market demand.
- Strong Cash Position: As of December 31, 2025, Codexis held $78.2 million in cash and short-term investments, which is expected to sufficiently fund its operations through the end of 2027, ensuring the smooth execution of its future development plans.
See More
Codexis Q1 2026 Earnings Call Insights
- Revenue Growth: Codexis reported total revenues of $15.2 million for Q1 2026, primarily driven by the Merck technology transfer agreement, indicating ongoing growth potential in the biocatalysis sector.
- R&D Investment: The company spent $11.4 million on R&D, resulting in a net loss of $8.7 million, yet maintained a 71% product gross margin, reflecting a shift towards higher-margin products in its portfolio.
- Market Opportunities: Codexis has over 50 opportunities in its sales pipeline with 40 companies showing strong continued interest, indicating rising market recognition and demand for its new technologies.
- Future Outlook: The company reiterated its revenue guidance for 2026 in the range of $72 million to $76 million, with expectations for revenue to be more heavily weighted towards the second half, emphasizing the commercialization potential of its ECO Synthesis technology and upcoming important data releases.
See More
U.S. Stocks Decline, Dow Jones Falls Over 400 Points
- Dow Jones Decline: The Dow Jones Industrial Average fell over 400 points on Thursday, down 1.01% to 46,936.20, indicating growing concerns about the economic outlook that may dampen investor confidence.
- NASDAQ and S&P 500 Drop: The NASDAQ decreased by 1.28% to 22,425.83, while the S&P 500 also fell 1.01% to 6,707.25, reflecting widespread weakness in both tech and large-cap stocks.
- Dollar General Earnings Beat: Dollar General reported Q4 earnings of $1.93 per share, exceeding analyst expectations of $1.65, yet its stock fell approximately 7%, indicating market caution regarding future prospects.
- Commodity Market Fluctuations: Oil prices surged 8.5% to $94.64, while gold dipped 0.3% to $5,164.30, reflecting investors' search for safe-haven assets amid an uncertain market environment.
See More
U.S. Stocks Drop Over 500 Points in Morning Trading
- Market Performance: U.S. stocks opened lower on Thursday, with the Dow Jones dropping over 500 points, a decline of 1.18% to 46,860.18, indicating a weak market sentiment.
- Sector Dynamics: Financial stocks fell by 1.4% during trading, while energy shares rose by 0.4%, reflecting mixed reactions across sectors that could influence investors' asset allocation strategies.
- Jobless Claims: Initial jobless claims in the U.S. decreased by 1,000 to 213,000, below market expectations of 215,000, indicating resilience in the labor market that may positively impact economic outlook.
- International Market Reaction: Asian markets closed lower, with Japan's Nikkei 225 down 1.04% and Hong Kong's Hang Seng index down 0.70%, suggesting that global market uncertainties may affect investor confidence.
See More
CODEXIS STOCK JUMPS 65% FOLLOWING INCREASED Q4 REVENUE
- Company Performance: Codexis shares soared by 65% following a strong revenue report for the fourth quarter.
- Revenue Growth: The increase in share value is attributed to higher-than-expected revenue figures released by the company.
See More
Codexis Reports Strong Q4 2025 Results, Shares Rise
- Earnings Beat: Codexis (CDXS) reported Q4 2025 revenue of $38.9 million, reflecting approximately 81% year-over-year growth and exceeding Street forecasts by $3.1 million, primarily driven by a technology transfer agreement with Merck (MRK), indicating robust growth in the enzyme engineering sector.
- Net Income Improvement: The company achieved a net income of $9.6 million in Q4, compared to a net loss of $10.4 million in the prior year, beating consensus estimates by $0.14 per share, which signifies a substantial improvement in profitability and boosts investor confidence.
- Annual Performance Gains: Codexis reduced its net loss by approximately 33% year-over-year to $44 million, with total revenue increasing about 19% to $70.4 million, while product gross margin improved from 56% in 2024 to 64%, reflecting effective cost control and sales strategies.
- Positive Outlook: The company projects total revenue for 2026 to be between $72 million and $76 million, surpassing the consensus of $67.3 million, and indicates a cash runway extending through the end of 2027, showcasing strong financial health and future growth potential.
See More
Codexis Reports Strong Q4 and 2025 Results, Shares Surge 25%
- Significant Financial Improvement: Codexis reported a net profit of $9.6 million in Q4 2025, translating to earnings of $0.11 per share, a stark reversal from a net loss of $10.37 million in the prior year, indicating a substantial enhancement in the company's profitability.
- Revenue Surge: The company experienced an 81% year-over-year increase in total revenue for Q4 2025, reaching $38.92 million, primarily driven by the Merck Technology Transfer Agreement, showcasing its competitive edge and business expansion capabilities.
- Optimistic Future Outlook: Codexis anticipates total revenue for 2026 to range between $72 million and $76 million, reflecting a projected growth of approximately 2% to 8% from 2025, which underscores the company's confidence in future growth and sustained market demand.
- Strong Cash Position: As of December 31, 2025, Codexis held $78.2 million in cash and short-term investments, which is expected to sufficiently fund its operations through the end of 2027, ensuring the smooth execution of its future development plans.
See More
